Oura Pursues FDA Clearance for Blood Pressure Monitoring Feature in Smart Ring
核心洞察
Oura (搜索) has received FDA approval to study a blood pressure monitoring feature for its smart rings, combining user health questionnaires with ring sensor data to assess hypertension risk.
The experimental feature will categorize users into "no signs," "moderate signs," or "major signs" of high blood pressure without requiring a traditional blood pressure cuff.
The company plans to launch the validation study in the U.S. this year through its Oura (搜索) Labs platform, targeting users 22 and older with generation 3 or 4 rings.
Oura (搜索), the smart ring manufacturer, has received Food and Drug Administration approval to study a blood pressure monitoring feature for its wearable devices, marking a significant step toward clinical validation of consumer health technology. The company announced Monday that it has engaged with the FDA and obtained institutional review board approval to validate the experimental feature among users enrolled in its testing program.
Blood Pressure Profile Development
The planned feature, termed a "blood pressure profile," will assess hypertension risk without requiring a traditional blood pressure cuff. Instead, the system will combine data from Oura (搜索)'s smart ring sensors with user-provided health information to categorize individuals into three risk levels: "no signs," "moderate signs," or "major signs" of high blood pressure. Users identified with major signs will be advised to seek medical consultation.
Oura (搜索)'s smart rings currently collect physiological data including heart rate, body temperature, blood oxygen levels, and activity metrics. The blood pressure feature will leverage this continuous monitoring capability alongside user questionnaires covering family history, medications, and lifestyle habits to generate risk assessments.
Study Design and Validation
The validation study will launch in the United States this year, targeting Oura (搜索) members who participate in experimental device features. Eligible participants must be at least 22 years old, based in the U.S., using the English-language app version, and own a generation 3 or 4 Oura ring. The study excludes pregnant individuals, those less than 12 weeks postpartum, and users with cardiac implants such as pacemakers.
According to Oura (搜索)'s statement, the study aims to "uncover how subtle physiological shifts can indicate chronic elevated blood pressure risk" by integrating continuous device data with research-grade measurements. The algorithm will track changes over time and provide early alerts about potential hypertension.
Regulatory Strategy and Market Position
The blood pressure feature represents Oura (搜索)'s broader push into clinical applications beyond its consumer device origins. CEO Tom Hale previously indicated the company's FDA approval intentions to CNBC, shortly before Dexcom (搜索)'s $75 million investment in the smart ring manufacturer. The company recently completed a $900 million funding round, providing resources for its regulatory strategy.
Study Access and Timeline
Oura (搜索) initially announced the study would be available through the Oura Labs section of its mobile application, but later clarified that access will become available "in the coming months." The Oura Labs platform, accessible through the app's menu, showcases experimental features and provides links for member study enrollment.
The blood pressure monitoring capability positions Oura (搜索) to compete with established players in the hypertension detection space, including Apple (搜索) Watch's existing hypertension notifications. By focusing on passive monitoring through continuous physiological data collection, Oura aims to enable early detection of elevated blood pressure risk without requiring active user intervention or additional medical devices.